View Document Preview and Link Document Date: 2009-06-03 10:36:53 Open Document File Size: 621,64 KB Share Result on Facebook
Company Propylamine Phenothiazines Piperidine Piperazine Conventional Butyrophenones Diphenylbutylpiperidines / / Continent Europe / / Country United Kingdom / / Facility National Institute of Mental Health PDSP / National Institute / / IndustryTerm natural chemicals / healthcare professionals / Drug / chemical structure / chemical structures / treatment of dementia-related behavioural disturbances / / MedicalCondition pulmonary arteries / cancer / schizophrenia / chest pain / dementia / hallucinations / Venous thrombosis / stroke / mania / diabetes / metabolic syndrome / blood clots / pain / Alzheimer's dementia / deep vein thrombosis / obesity / Parkinson’s disease / blood clot / venous thromboembolism / bipolar affective disorder / pulmonary embolism / neuroleptic malignant syndrome / thrombus / dizziness / constipation / eventual embolism / depression / extrapyramidal movement disorders / / MedicalTreatment surgery / / Organization MHRA / European Union / VTE association / Institute of Mental Health PDSP / Medicines and Healthcare products Regulatory Agency / National Institute for Clinical Excellence / / Position Executive / / Product olanzapine / clozapine / fluphenazine / haloperidol / Most / Risperdal / M-16 / Stelazine / Seroquel / Haldol / Antipsychotics Antipsychotic / risperidone / Abilify / Prochlorperazine / Perphenazine / Zyprexa / Clozaril / / ProgrammingLanguage php / / ProvinceOrState Prince Edward Island / / Technology Drug Screening / / URL http / SocialTag 
MHRA PUBLIC ASSESSMENT REPORT The risk of venous thromboembolism associated with antipsychotics June 2009 Executive summary 2